Bacillus Calmette-Guerin (BCG) endophthalmitis.
A patient who had been treated for metastatic bladder carcinoma with bacillus Calmette-Guerin (BCG) vaccine subsequently developed bilateral visual loss secondary to an infiltrative retinitis and vitreitis. Although assumed to have candida endophthalmitis, vitrectomy demonstrated mycobacterium bovis. The patient was placed on systemic anti-tuberculous therapy, and there was noted to be a reduction in retinal lesions prior to his death. This is the first report in the literature documenting endogenous endophthalmitis after BCG usage.
Lester
H
H
Division of Ophthalmology, North Shore University Hospital, Manhasset, New York.
Erdey
R A
RA
Fastenberg
D M
DM
Schwartz
P L
PL
Rosenhaus
J B
JB
D000368:Aged; D001500:BCG Vaccine / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009164:Mycobacterium Infections / Q000209:etiology*; D009163:Mycobacterium bovis / Q000302:isolation & purification; D012173:Retinitis / Q000209:etiology*; D001749:Urinary Bladder Neoplasms / Q000628:therapy; D014822:Vitreous Body / Q000382:microbiology
D001500:BCG Vaccine